Cargando…
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. The disease is usually detected in an advanced stage which precludes curative treatment. We assume that only new and non-invasive biomarkers allowing earlier detection will result in better patient management and...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581147/ https://www.ncbi.nlm.nih.gov/pubmed/28881848 http://dx.doi.org/10.18632/oncotarget.17910 |